MRK Stock Recent News

Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its current market price, MRK is as much as 23% undervalued. Underlying fundamentals are still strong, with great margins, heavy R&D investing, and a plan to aggressively expand by CapEx spending totaling $20 billion from 2024 to 2028.

I've written this kind of article before, addressing whether it's smart to buy into the dividend-paying stocks in the S&P 500 or Nasdaq Composite that have the highest dividend yields. There are some important things to know and to consider, and they're true when you're looking at stocks in the Dow Jones Industrial Average too.

Merck Mercuriadis is launching a fresh version of Hipgnosis Songs Fund Limited (LSE:SONG), the music rights venture he founded in 2018, as investors return to the sector following a bruising correction. In an interview with the Financial Times, the former Guns N' Roses manager said his new business would give artists and managers majority ownership, shifting power from record labels.

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.3%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 9%.

In the latest trading session, Merck (MRK) closed at $80.93, marking a -1.77% move from the previous day.

Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) seeking approval to update the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk). In 2024, WINREVAIR was approved for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1.

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, though still a bit short of my 12% annualized target. The July 2025 Top 15 stocks offer a 1.38% average dividend yield with an 18.78% 5-year dividend growth rate and are 23% undervalued.

Tech stocks lagged after a very strong first half of the year, while healthcare led the way.